Interestingly, the same study demonstrated that increased skeletal FGF-23 expression during inflammation remained even after the administration of the PHD inhibitor FG-4592 [166] (roxadustat—one of the PHD inhibitors currently in clinical trials for CKD treatment [167]). The gene discussed is FGF23; the disease is chronic kidney disease.